|
|
Article: Anadys, Roche Add Another Indication To Research Plans.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Building on an already once-expanded relationship, Anadys Pharmaceuticals Inc. and F. Hoffmann-La Roche Ltd. added an undisclosed program to their efforts, which means more research and development funding, plus potential milestone payments and royalties for Anadys.
"It's a completely different therapeutic area," said Kleanthis Xanthopoulos, San Diego-based Anadys' president and CEO, adding that research is at the preclinical stage but Roche, of Basel, Switzerland, "has clinical experience with this particular indication."
The firms began their partnership in August 2002, using Anadys' medicinal chemistry, structure-based drug ...
Related newspaper, magazine, and journal articles:
|
|
Article: ANADYS LANDS ITS LARGEST DEAL, SIGNS COLLABORATION WITH ...
BIOWORLD Today;
August 9, 2002 ;
700+ words
... ... plenty of meaning for Anadys, both financially and ... collaboration for us," he told BioWorld Today. "It involves a multimillion ... process." In June, Anadys and Gilead Sciences ... antiviral compounds using Anadys' technology and an ... and royalties. (See BioWorld Today, June 11, ...
|
|